Detection and Prediction of Clinically Significant Pneumothorax After Image-guided Transthoracic Lung Biopsy

ConditionLung Biopsy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese University of Hong Kong

About this trial

Objective: The goal of this study is to evaluate the sensitivity and specificity of the presence of pneumothorax on a 4-hour CXR after image-guided transthoracic lung biopsy (TTLB) for diagnosing subsequent clinically significant pneumothorax.

Hypothesis to be tested: The investigators hypothesize that an absence of pneumothorax on CXR at 4 hours can accurately predict an absence of clinically significant pneumothorax at 16 to 20 hours.

Design and subjects: This is a prospective, single-centre, diagnostic accuracy study conducted at a tertiary referral centre in Hong Kong. Patients will be recruited if an image-guided TTLB is arranged.

Study instruments: CXRs will be performed for patients at different time points. The presence and size of pneumothorax (if any) will be recorded.

Outcome: The diagnostic capacity of a 4-hour CXR after image-guided TTLB will be provide evidence regarding the safety and patient selection for same-day discharge.

Eligibility criteria

Qualifiers

Patients whose image-guided TTLB, including ultrasound or CT-guided, is arranged for diagnostic purposes

Patients who are able to sign written informed consent to participate in the study

Disqualifiers

Patients with resolution of lung lesion prior to the scheduled image-guided TTLB

Patients have active exacerbation of underlying diseases causing unstable respiratory conditions (e.g. exacerbation of COPD, pneumonia) which would lower the threshold for invasive interventions for iatrogenic pneumothorax

Patients with psychiatric disease or cognitive impairment that may limit their ability to understand or give consent to the study

Patients who decline to join the study

Trial design

Treatments tested in this trial

  • CXR

Treatment groups

330 Participants
are divided into 1 treatment group